Effects of bezafibrate on the serum lipoprotein lipid and apolipoprotein composition, lipoprotein triglyceride removal capacity and the fatty acid composition of the plasma lipid esters.
D000328:Adult; D001053:Apolipoproteins / Q000097:blood*; D001629:Bezafibrate; D001786:Blood Glucose; D001835:Body Weight; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000031:analogs & derivatives*; D002995:Clofibric Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology; D004952:Esters; D005227:Fatty Acids / Q000097:blood; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000494:pharmacology*; D008077:Lipoproteins, LDL / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood
D001053:Apolipoproteins; D001786:Blood Glucose; D004952:Esters; D005227:Fatty Acids; D007328:Insulin; D008055:Lipids; D008074:Lipoproteins; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D014280:Triglycerides; D002995:Clofibric Acid; D002784:Cholesterol; D002994:Clofibrate; D001629:Bezafibrate